Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Stock Has Average Price Target of $13.86 According to Brokerages

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has been assigned an average rating of “Hold” from the nine analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $13.86.

Several research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Wednesday, July 8th. Needham & Company LLC lowered their price target on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, Citigroup restated a “market outperform” rating on shares of Bicycle Therapeutics in a report on Wednesday, June 3rd.

Bicycle Therapeutics Price Performance

Shares of BCYC opened at $3.65 on Friday. The company has a market capitalization of $255.47 million, a price-to-earnings ratio of -1.34 and a beta of 1.54. Bicycle Therapeutics has a fifty-two week low of $3.57 and a fifty-two week high of $9.16. The business’s 50-day moving average is $4.00 and its 200-day moving average is $4.34.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.14). The company had revenue of $0.63 million during the quarter, compared to analysts’ expectations of $4.22 million. Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%. Equities research analysts expect that Bicycle Therapeutics will post -2.26 earnings per share for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 5,905 shares of Bicycle Therapeutics stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total transaction of $25,214.35. Following the completion of the sale, the chief executive officer owned 605,408 shares of the company’s stock, valued at approximately $2,585,092.16. This trade represents a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 9,977 shares of company stock worth $42,702 over the last ninety days. 22.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in BCYC. Portland Investment Counsel Inc. acquired a new stake in shares of Bicycle Therapeutics during the 2nd quarter valued at about $64,000. Marquette Asset Management LLC acquired a new position in Bicycle Therapeutics in the second quarter worth approximately $309,000. FNY Investment Advisers LLC increased its holdings in Bicycle Therapeutics by 247.4% in the second quarter. FNY Investment Advisers LLC now owns 26,250 shares of the company’s stock worth $111,000 after buying an additional 18,693 shares during the last quarter. GAMMA Investing LLC raised its position in Bicycle Therapeutics by 512.9% during the second quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock valued at $33,000 after acquiring an additional 6,447 shares in the last quarter. Finally, Flax Pond Capital LLC raised its position in Bicycle Therapeutics by 1.4% during the first quarter. Flax Pond Capital LLC now owns 176,136 shares of the company’s stock valued at $817,000 after acquiring an additional 2,503 shares in the last quarter. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage biopharmaceutical company developing medicines based on its proprietary Bicycle technology. The platform uses small, constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and manufacturing advantages of small molecules with the target specificity often associated with larger biologic medicines.

The company’s research and development activities are focused primarily on oncology.